Literature Search Strategy

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: abobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada Inc.): Indication: For the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug.

Cover of Clinical Review Report: abobotulinumtoxinA (Dysport Therapeutic)

Clinical Review Report: abobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada Inc.): Indication: For the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older [Internet].

Show details

Contents

< Prev Next >

Appendix 2Literature Search Strategy

OVERVIEW
Interface:	Ovid
Databases:	Embase 1974 to present MEDLINE ALL 1946 to present Note: Subject headings have been customized for each database. Duplicates between databases were removed in Ovid.
Date of Search:	March 8 2018
Alerts:	Weekly search updates until July 18 2018
Study Types:	No search filters were applied
Limits:	No date or language limits were used Conference abstracts were excluded
SYNTAX GUIDE
/	At the end of a phrase, searches the phrase as a subject heading
.sh	At the end of a phrase, searches the phrase as a subject heading
MeSH	Medical Subject Heading
fs	Floating subheading
exp	Explode a subject heading
*	Before a word, indicates that the marked subject heading is a primary topic; or, after a word, a truncation symbol (wildcard) to retrieve plurals or varying endings
#	Truncation symbol for one character
?	Truncation symbol for one or no characters only
adj#	Adjacency within # number of words (in any order)
.ti	Title
.ab	Abstract
.ot	Original title
.hw	Heading word; usually includes subject headings and controlled vocabulary
.kf	Author keyword heading word (MEDLINE)
.kw	Author keyword (Embase)
.pt	Publication type
.po	Population group [PsycInfo only]
.rn	CAS registry number
.nm	Name of substance word
pmez	Ovid database code; MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE Daily and Ovid MEDLINE 1946 to Present
oemezd	Ovid database code; Embase 1974 to present, updated daily

MULTI-DATABASE STRATEGY
1.	exp Botulinum Toxins, Type A/
2.	(Abobotulinum* or bobotulinum* or abo botulinum* or Dysport* or Azzalure* or Reloxin* or CNT52120 or CNT 52120 or aboA or abo A or ABO or AboBTXA or aboBoNT A or aboBoNTA or “953397358” or 95339735 8 or 953397 358).ti,ab,kf,ot,hw,rn,nm.
3.	(BoNT or BoNTA* or BTA or BTXA or BTX A or BTX).ti,ab,kf,ot,hw,rn,nm.
4.	(botulin* adj3 (typeA or type A)).ti,ab,kf,ot,hw,rn,nm.
5.	(botulinumtoxintypeA or botulinumtoxinA or botulin A or botulin toxin A or BoNT?A or botulinum neurotoxin* or botulinum neuro toxin*).ti,ab,kf,ot,hw,rn,nm.
6.	1 or 2 or 3 or 4 or 5
7.	exp Lower extremity/
8.	(lower adj2 (limb* or extremit* or bod*)).ti,ab,kf.
9.	Membrum inferius.ti,ab,kf.
10.	(leg* or hip* or knee* or buttock* or toe* or foot or feet or thigh* or calf or calves or hamstring* or quadricep* or adductor* or soleus or gastrocnem* or equin* or gait).ti,ab,kf.
11.	7 or 8 or 9 or 10
12.	exp muscle spasticity/
13.	(spas* or rigidity* or hyperton*).ti,ab,kf.
14.	exp paraparesis, spastic/
15.	12 or 13 or 14
16.	6 and 11 and 15
17.	16 use medall
18.	*botulinum toxin a/
19.	(Abobotulinum* or bobotulinum* or abo botulinum* or Dysport* or Azzalure* or Reloxin* or CNT52120 or CNT 52120 or aboA or abo A or ABO or AboBTXA or aboBoNT A or aboBoNTA or “953397358” or 95339735 8 or 953397 358).ti,ab,kw.
20.	(BoNT or BoNTA* or BTA or BTXA or BTX A or BTX).ti,ab,kw.
21.	(botulin* adj3 (typeA or type A)).ti,ab,kw.
22.	(botulinumtoxintypeA or botulinumtoxinA or botulin A or botulin toxin A or BoNT?A or botulinum neurotoxin* or botulinum neuro toxin*).ti,ab,kw.
23.	18 or 19 or 20 or 21 or 22
24.	lower limb/
25.	(lower adj2 (limb* or extremit* or bod*)).ti,ab,kw.
26.	Membrum inferius.ti,ab,kw.
27.	(leg* or hip* or knee* or buttock* or toe* or foot or feet or thigh* or calf or calves or hamstring* or quadricep* or adductor* or soleus or gastrocnem* or equin* or gait).ti,ab,kw.
28.	24 or 25 or 26 or 27
29.	muscle spasm/
30.	spasticity/
31.	(spas* or rigidity* or hyperton*).ti,ab,kw.
32.	29 or 30 or 31
33.	23 and 28 and 32
34.	33 use oemezd
35.	17 or 34
36.	conference abstract.pt.
37.	35 NOT 36
38.	Remove duplicates

OTHER DATABASES
PubMed	A limited PubMed search was performed to capture records not found in MEDLINE. Same MeSH, keywords, limits, and study types used as per MEDLINE search, with appropriate syntax used.
Trial registries (Clinicaltrials.gov and others)	Same keywords, limits used as per MEDLINE search.

Grey Literature

Dates for Search:	March 2018
Keywords:	Dysport AND Spasticity
Limits:	No date or language limits used

Relevant websites from the following sections of the CADTH grey literature checklist Grey Matters: a practical tool for searching health-related grey literature (https://www.cadth.ca/grey-matters) were searched:

Health Technology Assessment Agencies
Health Economics
Clinical Practice Guidelines
Drug and Device Regulatory Approvals
Advisories and Warnings
Drug Class Reviews
Databases (free)
Internet Search.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK540261

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Clinical Review Report: abobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada Inc.): Indication: For the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug. Appendix 2, Literature Search Strategy.
PDF version of this title (962K)